Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ASKG712, VIS-101 High concentration, AM712
VIS-101 · 3 trials · 3 indications
BCVA as measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity
Any relevant ocular observations derived from best corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, ophthalmoscopy, optical coherence tomography (OCT), fundus photography, and angiography
Any clinical safety observations assessed by physical examination, vital signs, electrocardiograph (ECG) and clinical laboratory tests
Any changes of clinical safety observations assessed by vital signs, electrocardiograph (ECG), clinical laboratory tests and physical examination
| Arm | Type | Description |
|---|---|---|
| VIS-101 6.0mg Low concentration | EXPERIMENTAL | VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol. |
| VIS-101 6.0mg High concentration | EXPERIMENTAL | VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol. |
| VIS-101 9.0mg High concentration | EXPERIMENTAL | VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol. |
| Aflibercept | ACTIVE_COMPARATOR | Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W). |
| ASKG712 | EXPERIMENTAL | Multiple doses of ASKG712 by intravitreal injection |
| Name | Type | Description |
|---|---|---|
| VIS-101 6.0mg High concentration | BIOLOGICAL | VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol. |
| VIS-101 9.0mg High concentration | BIOLOGICAL | VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol. |
| Aflibercept (Eylea) | BIOLOGICAL | Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W). |
| ASKG712 | BIOLOGICAL | ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2. |
Inclusion Criteria: 1. Willingness to sign the informed consent form, aged ≥50 years (on Day 0 of dosing), with no gender restrictions 2. Able to adhere to the study protocol per the Investigator judgment 3. Female participants of childbearing potential (WOCBP) or male participants with partners wh...
Top 16 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| 4D Molecular Therapeutics, Inc. | FDMT | 2 | PHASE3 | 4D-150, EYELEA |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Hoffmann-La Roche | RHHBY | 6 | PHASE3 | Ranibizumab, Susvimo, RO7497372, RO7823653, Faricimab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | MK-8748 |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | Surabgene Lomparvovec |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tabirafusp tedromer |
| Alvotech | ALVO | 1 | PHASE3 | AVT29 |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 |
| BioAge Labs, Inc. | BIOA | 1 | PHASE2 | BGE-102 |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Surrozen Inc | SRZN | 1 | PHASE1 | SZN-8141 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
| Bayer | BAYRY | 1 | - | Aflibercept |
VIS-101 is an investigational monoclonal antibody developed by NovaBridge Biosciences for retinal diseases. It is being studied in ophthalmology for two conditions: diabetic macular edema and neovascular age-related macular degeneration. It is a clinical-stage asset, not an approved therapy, and has been tested in early-phase trials in China.
VIS-101 is being developed for the treatment of diabetic macular edema and neovascular age-related macular degeneration, two retinal conditions involving abnormal blood vessel growth and leakage. Both indications are in clinical development, so VIS-101 is not yet an approved treatment for either condition.
VIS-101 targets both VEGF-A and ANG2, two signaling proteins involved in angiogenesis and vascular instability in the retina. Dual targeting of these pathways is the mechanism under investigation for reducing abnormal vessel growth and leakage in diabetic macular edema and neovascular age-related macular degeneration.
VIS-101 is developed by NovaBridge Biosciences, which trades under the ticker NBP. The company is advancing the monoclonal antibody across ophthalmology indications, with clinical work conducted under the ASKG712 designation in China before the program moved into later-stage planning.
VIS-101 is in Phase 1 development overall, with completed Phase 1 studies in diabetic macular edema and neovascular age-related macular degeneration. A Phase 2 study in neovascular age-related macular degeneration is planned but not yet recruiting. VIS-101 is investigational and has not been approved by the FDA.
VIS-101 has been studied in NCT05940428, a completed Phase 1 trial in diabetic macular edema with 10 participants in China, and NCT05456828, a completed Phase 1 trial in neovascular age-related macular degeneration with 56 participants in China. A Phase 2 trial, NCT07798375, is planned in neovascular age-related macular degeneration with 244 participants and is not yet recruiting.
Yes, ASKG712 is an alternative name for VIS-101, the monoclonal antibody developed by NovaBridge Biosciences. The Phase 1 trials in China were run under the ASKG712 designation, while the program is now referred to as VIS-101, including a high concentration 6.0 mg formulation.